Biocon Closes $3bn Deal For Viatris Biosimilars

Cites ‘Historic Inflection Point’ For Biocon Biologics As Viatris Also Begins Transformation

 
• By David Wallace
  
$3 billion icon blue
The deal value comprises $2bn cash upfront and a $1bn share issue • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business